This CEO's Controversial Interview Tactic Could Be the Secret to Hiring the Right People: 'Wondering If I'm Insane or Brilliant'
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report? Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel. Previous Article Six Flags is a Ride You Don’t Want to Get Stuck On Next Article Roasted Green Beans
